Search 

Nanovista is a biotechnology company based out of JLABS @ Toronto that is developing technologies to improve the outcomes of cancer surgeries. Nanovista’s lead program, CF800, is a novel imaging agent that enables the real-time visualization of solid tumors during cancer surgery.

Nenupharma was born out of a shared passion to contribute to the development of innovative pharmaceuticals in different disease areas.

Nenupharma uses the best of skills that have been developed through an extensive career in pharmaceutical industry, regulatory affairs, market access, medical practice and life science.

Nenupharma has been working with high level experts on different levels and enjoys reliable, professional and ethical reputation among its network as well as its customers.

For more information, visit our website at:
www.nenupharma.com

Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)

NLC European Healthcare Venture Builder 是一家总部位于荷兰的欧洲医疗科技企业创设公司,在法国、德国和奥地利设有分支机构。NLC 每年筛选超过 3,000 项欧洲最新的医疗专利技术和发明,从中挑选出最具潜力的创新技术并创建公司。NLC 旗下已拥有数十家医疗科技企业,横跨治疗设备、诊断、影像、细胞疗法、AI 人工智能、神经网络、智慧医疗等国内热门医疗领域和紧缺方向,且在技术成熟度、治疗领域和技术类型上拥有充分的多样性,进一步分散了投资风险。

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

华诺临床立足于海外,为全球客户提供医药产品在北美进行 FDA 临床报批、临床试验运营、临床数据分析与管理等一系列服务。专业的团队,丰富的经验以及客户至上的合作理念会助您拓展在海外的临床开发业务。客户的满意与成功是我们追求的终极目标。

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/out-licensing of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.